Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19261937 | 1.00 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL691498 | 1.00 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL12103325 | 1.00 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1104912 | 1.00 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL8222457 | 1.00 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL7309908 | 0.95 | KLK5 (0.65) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL7303561 | 0.92 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL7309398 | 0.92 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL5945448 | 0.91 | REN (0.54) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL13630987 | 0.91 | REN (0.54) | KLK5ATMPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216990-B2 | Crystalline Darunavir | MYLAN LABS LIMITED (IN) | 2015-12-22 | — | — | US | disclosed |
| US-20140350270-A1 | Crystalline Darunavir | Mylan Laboratores LTD (IN) | 2014-11-27 | — | — | US | disclosed |
| US-8076513-B2 | Methods for the preparation of N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-12-13 | — | — | US | disclosed |
| EP-2152667-B1 | METHODS FOR THE PREPARATION OF N-ISOBUTYL-N-(2-HYDROXY-3-AMINO-4-PHENYLBUTYL)-P-NITROBENZENESULFONYLAMIDE DERIVATIVES | TIBOTEC PHARM LTD (IE) | 2011-02-16 | — | — | EP | disclosed |
| US-20100121094-A1 | METHODS FOR THE PREPARATION OF N-ISOBUTYL-N-(2-HYDROXY-3-AMINO-4-PHENYLBUTYL)-P-NITROBENZENESULFONYLAMIDE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD | 2010-05-13 | — | — | US | disclosed |
| US-7595334-B2 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-09-29 | — | — | US | disclosed |
| US-7244752-B2 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-17 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20040132791-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-07-08 | — | — | US | disclosed |
| US-6573388-B1 | Synthetic intermediates for the synthesis of HIV protease inhibitors and oligopeptide mimetics | SAMCHULLY PHARM. CO., LTD. (KR) | 2003-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350270-A1 | Crystalline Darunavir | SAMHD1, DARS1, DUT | KLK5 71/4885ATM 2718/4885PSEN1 2473/4885 |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | NR0B1, NR0B2, NR2C2 | KLK5 4849/4885ATM 4477/4885PSEN1 2123/4885 |
| US-20040132791-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | ALOX15B, CYP2B6, ALOX12 | KLK5 4885/4885ATM 4079/4885PSEN1 2296/4885 |
| US-20100121094-A1 | METHODS FOR THE PREPARATION OF N-ISOBUTYL-N-(2-HYDROXY-3-AMINO-4-PHENYLBUTYL)-P-NITROBENZENESULFONYLAMIDE DERIVATIVES | DNPEP, NPEPPS, ASNS | KLK5 3247/4885ATM 4096/4885PSEN1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.